Zynerba Pharmaceuticals: Analysts See More
Upside after the Rally
More
Zynerba Pharmaceuticals:
Analysts See More Upside after the RallyZynerba PharmaceuticalsSo
far, Zynerba Pharmaceuticals (ZYNE) has seen an upwards price
action of 265% in 2019. Analysts see more upside in the stock. The
mean consensus target price